Title |
|
Title |
1 |
Identify the study as an economic evaluation and specify the interventions being compared. |
_______ |
Abstract |
|
Abstract |
2 |
Provide a structured summary that highlights context, key methods, results, and alternative analyses. |
_______ |
Introduction |
|
Background and objectives |
3 |
Give the context for the study, the study question, and its practical relevance for decision making in policy or practice. |
_______ |
Methods |
|
Health economic analysis plan |
4 |
Indicate whether a health economic analysis plan was developed and where available. |
_______ |
Study population |
5 |
Describe characteristics of the study population (such as age range, demographics, socioeconomic, or clinical characteristics). |
_______ |
Setting and location |
6 |
Provide relevant contextual information that may influence findings. |
_______ |
Comparators |
7 |
Describe the interventions or strategies being compared and why chosen. |
_______ |
Perspective |
8 |
State the perspective(s) adopted by the study and why chosen. |
_______ |
Time horizon |
9 |
State the time horizon for the study and why appropriate. |
_______ |
Discount rate |
10 |
Report the discount rate(s) and reason chosen. |
_______ |
Selection of outcomes |
11 |
Describe what outcomes were used as the measure(s) of benefit(s) and harm(s). |
_______ |
Measurement of outcomes |
12 |
Describe how outcomes used to capture benefit(s) and harm(s) were measured. |
_______ |
Valuation of outcomes |
13 |
Describe the population and methods used to measure and value outcomes. |
_______ |
Measurement and valuation of resources and costs |
14 |
Describe how costs were valued. |
_______ |
Currency, price date, and conversion |
15 |
Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion. |
_______ |
Rationale and description of model |
16 |
If modelling is used, describe in detail and why used. Report if the model is publicly available and where it can be accessed. |
_______ |
Analytics and assumptions |
17 |
Describe any methods for analysing or statistically transforming data, any extrapolation methods, and approaches for validating any model used. |
_______ |
Characterising heterogeneity |
18 |
Describe any methods used for estimating how the results of the study vary for subgroups. |
_______ |
Characterising distributional effects |
19 |
Describe how impacts are distributed across different individuals or adjustments made to reflect priority populations. |
_______ |
Characterising uncertainty |
20 |
Describe methods to characterise any sources of uncertainty in the analysis. |
_______ |
Approach to engagement with patients and others affected by the study |
21 |
Describe any approaches to engage patients or service recipients, the general public, communities, or stakeholders (such as clinicians or payers) in the design of the study. |
_______ |
Results |
|
Study parameters |
22 |
Report all analytic inputs (such as values, ranges, references) including uncertainty or distributional assumptions. |
_______ |
Summary of main results |
23 |
Report the mean values for the main categories of costs and outcomes of interest and summarise them in the most appropriate overall measure. |
_______ |
Effect of uncertainty |
24 |
Describe how uncertainty about analytic judgments, inputs, or projections affect findings. Report the effect of choice of discount rate and time horizon, if applicable. |
_______ |
Effect of engagement with patients and others affected by the study |
25 |
Report on any difference patient/service recipient, general public, community, or stakeholder involvement made to the approach or findings of the study |
_______ |
Discussion |
|
Study findings, limitations, generalisability, and current knowledge |
26 |
Report key findings, limitations, ethical or equity considerations not captured, and how these could affect patients, policy, or practice. |
_______ |
Other relevant information |
Source of funding |
27 |
Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis |
_______ |
Declaration of Competing Interest |
28 |
Report authors conflicts of interest according to journal or International Committee of Medical Journal Editors requirements. |
_______ |